Eric Lefkofsky Sells 22,335 Shares of Tempus AI (NASDAQ:TEM) Stock

Tempus AI, Inc. (NASDAQ:TEM) CEO Eric Lefkofsky sold 22,335 shares of the business’s stock in a transaction that occurred on Tuesday, May 19th. The stock was sold at an average price of $44.07, for a total transaction of $984,303.45. Following the completion of the transaction, the chief executive officer directly owned 2,230,721 shares of the company’s stock, valued at approximately $98,307,874.47. This represents a 0.99% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Tempus AI Price Performance

TEM stock opened at $46.18 on Friday. Tempus AI, Inc. has a one year low of $41.73 and a one year high of $104.32. The stock has a market cap of $8.29 billion, a PE ratio of -26.85 and a beta of 3.99. The firm has a 50 day simple moving average of $48.89 and a two-hundred day simple moving average of $59.29. The company has a debt-to-equity ratio of 2.96, a current ratio of 3.31 and a quick ratio of 3.15.

Tempus AI (NASDAQ:TEM) last released its earnings results on Tuesday, May 5th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.08. The company had revenue of $348.12 million for the quarter, compared to analyst estimates of $345.44 million. Tempus AI had a negative net margin of 22.20% and a negative return on equity of 53.83%. The firm’s quarterly revenue was up 36.1% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.24) EPS. On average, analysts predict that Tempus AI, Inc. will post -1.35 EPS for the current fiscal year.

Tempus AI News Summary

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Tempus launched the ArteraAI Prostate Test for metastatic patients, its first prostate digital pathology algorithm available for clinical use inside the Tempus ecosystem. The move expands its oncology platform and could deepen adoption with urologists and oncologists. Article Title
• Positive Sentiment: An analyst-style bullish take argued Tempus is benefiting from a large data estate, AI-driven products, and a contract backlog above $1 billion, suggesting the recent pullback may have created a more attractive valuation for risk-tolerant investors. Article Title

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Needham & Company LLC reissued a “buy” rating and issued a $75.00 target price on shares of Tempus AI in a research note on Wednesday, March 11th. Robert W. Baird assumed coverage on Tempus AI in a research note on Tuesday, February 17th. They issued an “outperform” rating and a $59.00 target price for the company. BTIG Research lowered their target price on Tempus AI from $90.00 to $80.00 and set a “buy” rating for the company in a research note on Friday, May 8th. Wall Street Zen lowered Tempus AI from a “hold” rating to a “sell” rating in a research note on Saturday, February 28th. Finally, Morgan Stanley dropped their price target on shares of Tempus AI from $85.00 to $70.00 and set an “overweight” rating for the company in a research report on Tuesday, March 3rd. Nine equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Tempus AI presently has a consensus rating of “Moderate Buy” and an average target price of $68.64.

Hedge Funds Weigh In On Tempus AI

A number of hedge funds have recently modified their holdings of TEM. Royal Bank of Canada grew its holdings in shares of Tempus AI by 201.2% in the 1st quarter. Royal Bank of Canada now owns 25,988 shares of the company’s stock worth $1,253,000 after acquiring an additional 17,359 shares during the last quarter. Rhumbline Advisers acquired a new position in shares of Tempus AI in the 1st quarter worth $116,000. Prudential Financial Inc. acquired a new position in shares of Tempus AI in the 2nd quarter worth $276,000. Russell Investments Group Ltd. grew its holdings in shares of Tempus AI by 21.3% in the 2nd quarter. Russell Investments Group Ltd. now owns 6,527 shares of the company’s stock worth $415,000 after acquiring an additional 1,146 shares during the last quarter. Finally, Invesco Ltd. grew its holdings in shares of Tempus AI by 2,926.6% in the 2nd quarter. Invesco Ltd. now owns 211,621 shares of the company’s stock worth $13,446,000 after acquiring an additional 204,629 shares during the last quarter. 24.22% of the stock is currently owned by institutional investors and hedge funds.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.